The GLP-1 receptor agonists: what’s all the (cardiovascular) hype about?

Authors

Keywords:

GLP-1 receptor agonists, cardiovascular disease, hypoglycaemic agents

Abstract

Over four million people in South Africa are estimated to have diabetes. People diagnosed with diabetes have an increased risk of developing cardiovascular disease. Safety trials conducted on novel hypoglycaemic agents suggest that glucagon-like peptide-1 receptor agonists may afford cardiovascular benefits in this at-risk population. Selection of an agent from this class, as add-on  treatment to metformin, should be individualised and based on accessibility, affordability, convenience of the dosing schedule, and tolerability.

Author Biographies

J Taylor, University of Cape Town

Division of Clinical Pharmacology, Department of Medicine, Groote Schuur Hospital, University of Cape Town, South Africa

R Mpofu, University of Cape Town

Division of Clinical Pharmacology, Department of Medicine, Groote Schuur Hospital, University of Cape Town, South Africa

M Blockman, University of Cape Town

Division of Clinical Pharmacology, Department of Medicine, Groote Schuur Hospital, University of Cape Town, South Africa

Downloads

Published

2024-11-06

Issue

Section

Review